论文部分内容阅读
目的:研究分析肺结核(TB)合并乙型病毒性感染(HBVI)患者中抗病毒治疗与保肝治疗的效果,为临床应用作出指导。方法:共选取了102例肺结核合并乙型肝炎病毒感染的患者,随机分为对照组和实验组各51例,对照组进行抗结核与抗病毒治疗,实验组再抗结核与抗病毒治疗的基础上再采取护肝治疗,对治疗前后两组肝功能指标、肺结核治疗效果进行比较。结果:实验组治疗后ALT、AST、TBIL各项肝功指标均比同期的对照组要低,实验组的治疗有效率(94.1%)要高于对照组(86.3%),上述差异具有统计学意义(P<0.05)。结论:在肺结核合并乙型肝炎感染患者中抗病毒联合保肝治疗,能够对肝脏起到更好的保护作用,保证抗结核治疗的顺利进行,具有临床普及应用的价值。
Objective: To study the effect of antiviral therapy and hepatoprotective therapy in patients with pulmonary tuberculosis (TB) complicated with viral hepatitis B (HBVI) and to provide guidance for clinical application. Methods: A total of 102 patients with pulmonary tuberculosis complicated with hepatitis B virus infection were selected and randomly divided into control group and experimental group, 51 cases each. The control group was treated with anti-TB and antiviral therapy. The anti-tuberculosis and anti-virus treatment On the treatment of liver protection, liver function index and treatment effect of tuberculosis were compared before and after treatment. Results: The indexes of ALT, AST and TBIL in experimental group were all lower than those in control group at the same period. The treatment effective rate (94.1%) in experimental group was higher than that in control group (86.3%), the difference was statistically significant Significance (P <0.05). Conclusion: Antiviral and hepatoprotective therapy in patients with pulmonary tuberculosis complicated with hepatitis B infection can play a better protective role on the liver, and ensure the smooth progress of antituberculosis treatment, which has the value of clinical popularization and application.